Scholarlink

<p>This study investigated the efficacy of supplementation with B vitamins and magnesium in alleviating fatigue, improving disease activity, and health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) based on patient-reported outcomes. In this randomized, double-blind, placebo-controlled trial, 98 adults with IBD in remission were randomized (1:1) to receive daily supplementation with vitamins B<sub>1</sub>, B<sub>6</sub>, B<sub>12</sub>, and magnesium or a matching placebo for 4 weeks. Outcomes were assessed using validated instruments, including the Inflammatory Bowel Disease Fatigue Scale (IBD-F), Patient-reported Simple Clinical Colitis Activity Index (P-SCCAI), Simplified Crohn’s Disease Activity Index (SCDAI), and the Short Inflammatory Bowel Disease Questionnaire (IBDQ-9). Compared with placebo, the intervention produced greater reductions in ulcerative colitis (UC) activity measured by P-SCCAI (β = −1.32; <i>p</i> = 0.006) and fatigue assessed by IBD-F Section&#xa0;1 (β = −1.98; <i>p</i> &lt; 0.001) and Section&#xa0;2 (β = − 5.19; <i>p</i> &lt; 0.001). No significant between-group differences were observed for Crohn’s disease activity (SCDAI; β = −3.93; <i>p</i> = 0.301) or HRQoL measured by IBDQ-9 (β = 1.21; <i>p</i> = 0.114). Supplementation with B vitamins and magnesium improved fatigue and symptom-based disease activity scores in UC; however, effects on underlying inflammatory activity remain uncertain.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of B vitamins and magnesium on fatigue, disease activity and quality of life in inflammatory bowel disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月21日

查看全文
  • Elmira Ramezani,
  • Palle Bager,
  • Kimia Torabinasab,
  • Nasser Ebrahimi Daryani,
  • Mehdi Azizmohammad Looha,
  • Mohammad Masoumvand,
  • Mohammad Taher,
  • Masoud Ashadzadeh,
  • Mohammadreza Vafa

摘要

This study investigated the efficacy of supplementation with B vitamins and magnesium in alleviating fatigue, improving disease activity, and health-related quality of life (HRQoL) in patients with inflammatory bowel disease (IBD) based on patient-reported outcomes. In this randomized, double-blind, placebo-controlled trial, 98 adults with IBD in remission were randomized (1:1) to receive daily supplementation with vitamins B1, B6, B12, and magnesium or a matching placebo for 4 weeks. Outcomes were assessed using validated instruments, including the Inflammatory Bowel Disease Fatigue Scale (IBD-F), Patient-reported Simple Clinical Colitis Activity Index (P-SCCAI), Simplified Crohn’s Disease Activity Index (SCDAI), and the Short Inflammatory Bowel Disease Questionnaire (IBDQ-9). Compared with placebo, the intervention produced greater reductions in ulcerative colitis (UC) activity measured by P-SCCAI (β = −1.32; p = 0.006) and fatigue assessed by IBD-F Section 1 (β = −1.98; p < 0.001) and Section 2 (β = − 5.19; p < 0.001). No significant between-group differences were observed for Crohn’s disease activity (SCDAI; β = −3.93; p = 0.301) or HRQoL measured by IBDQ-9 (β = 1.21; p = 0.114). Supplementation with B vitamins and magnesium improved fatigue and symptom-based disease activity scores in UC; however, effects on underlying inflammatory activity remain uncertain.